Ustekinumab

USDailyMed:Ustekinumab AU:B1 L04AC05(WHO) AU:S4(Prescription only)CA:℞-only/Schedule DUK:POM(Prescription only)US:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) 815610-63-0N DB05679Y none FU77B4U5Z0 D09214Y ChEMBL1201835N Ustekinumab, sold under the brand nameStelaraamong others, is amonoclonal antibodymedication used for the treatment ofCrohn's disease,ulcerative colitis,plaque psoriasisandpsoriatic arthritis,targeting both IL-12 and IL-23.It is administered either byintravenous infusionorsubcutaneous injection.The antibody tar‍‍‍‍‍‍​​​‍​​​​​​gets a subunit of humaninterleukin 12andinterleukin 23, which are naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders.Ustekinumab was developed by Centocor Ortho Biotech. Ustekinumab (an immunosuppressant interleukin inhibitor)is a fully human IgG1κ monoclonal antibody that binds to the shared p40 protein subunit of interleukin (IL) 12 and 23, thereby preventing them from binding to the IL-12Rβ1 receptor protein expressed on the surface of immune cells.By doing so, ustekinumab prevents the activation of the Th1 and Th17 cytokine pathways, which are central to the pathology of psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. Ustekinumab is approved to treat Crohn's disease in the United States, Israel, Australia, and the European Union; and ulcerative colitis in the United States, and in the European Union to people who have not responded to more traditional treatments.It was found not effective formultiple sclerosis.It is on theWorld Health Organization's List of Essential Medicines.